The GC–MS metabolomics signature in patients with fibromyalgia syndrome directs to dysbiosis as an aspect contributing factor of FMS pathophysiology
Fibromyalgia syndrome (FMS) is a chronic pain syndrome. Previous analyses of untargeted metabolomics data indicated altered metabolic profile in FMS patients.
We report a semi-targeted explorative metabolomics study on the urinary metabolite profile of FMS patients; exploring the potential of urinary metabolite information to augment existing medical diagnosis.
All cases were females. Patients had a medical history of persistent FMS (n = 18). Control groups were first-generation family members of the patients (n = 11), age-related individuals without indications of FMS (n = 10), and healthy, young (18–22 years) individuals (n = 41). The biofluid investigated was early morning urine samples. Data generation was done through gas chromatography–mass spectrometry (GC–MS) analysis and data processing and analyses were performed using Matlab, R, SPSS and SAS software.
Quantitative analysis revealed the presence of 196 metabolites. Unsupervised and supervised multivariate analyses distinguished all three control groups and the FMS patients, which could be related to 14 significantly increased metabolites. These metabolites are associated with energy metabolism, digestion and metabolism of carbohydrates and other host and gut metabolites.
Overall, urinary metabolite profiles in the FMS patients suggest: (1) energy utilization is a central aspect of this pain disorder, (2) dysbiosis seems to prevail in FMS patients, indicated by disrupted microbiota metabolites, supporting the model that microbiota may alter brain function through the gut-brain axis, with the gut being a gateway to generalized pain, and (3) screening of urine from FMS is an avenue to explore for adding non-invasive clinical information for diagnosis and treatment of FMS.
KeywordsFibromyalgia syndrome (FMS) Gas chromatography–mass spectrometry (GC–MS) Dysbiosis Carbohydrate Pain Biomarkers
American College of Rheumatology
Group of first-degree relatives of the patients
Group of healthy young subjects
Group of age-matched subjects but unrelated to the patients
Central nervous system
- EI and HP
A general and a histidine-containing cytoplasmic phosphor-carrier bacterial protein system
- EII-AT, EII-BT and EII-CT
Tagatose-specific B. licheniformis multi-domain membrane proteins
Enzyme Commission number
Fibromyalgia impact questionnaire
Functional pain syndromes
Gas chromatographic–mass spectrometric
Human metabolome database
Irritable bowel syndrome
In-house clinical questionnaire
National Institute of Standards and Technology
Proton nuclear magnetic resonance
Nuclear Technologies in Medicine and Biosciences Initiative
Principal components analysis
Partial least squares discriminant analysis
Phosphoenolpyruvate:carbohydrate phosphotransferase system
Predictive ability parameter
Small intestinal bacterial over-growth
Variable important in projection
Research funding for this project was provided by the Technological Innovation Agency (TIA) of the South African Department of Science and Technology (DST) and from the Nuclear Technologies in Medicine and the Biosciences Initiative (NTeMBI) of the Nuclear Energy Corporation of South Africa (NECSA). BM received a postgraduate bursary from the National Research Foundation (NRF) of South Africa.
This investigation required a multidisciplinary approach and the inputs of all authors were essential to produce the concept and final manuscript. CR and HM defined the aim of the study. The urine samples from the FMS patients and age-matched and family-related controls were provided by HM, who also performed all relevant clinical aspects, and acted as assistant promoter to BM. CR developed the experimental design, acted as the promoter for BM and arranged with HM for ethical approval for the study and for the collection of samples from the young controls. BM conducted all experimental analyses and compiled the clinical information provided by HM. LJM gave guidance and assessment on GC–MS data generation and analyses. RW was responsible for critical evaluation of the analytical aspects of the clinical chemistry data and for their interpretation. MvR performed all the statistical analyses. SM was responsible for coordination and integration of inputs from the authors who contributed to the manuscript as presented here.
Compliance with ethical standards
Conflict of interest
The authors declare that there are no competing interests regarding the publication of this paper.
Ethical approval for the study was obtained via a consortium under the Nuclear Technologies in Medicine and Biosciences Initiative (NTeMBI) of South Africa and ethical approval by Pharma Ethics Pty, Ltd (Reference number 11064365). Pharma Ethics confirmed the following: “The study has been accepted as complying to the Ethics Standards for Clinical Research with a new drug in participants based on FDA, ICH GCP and the Declaration of Helsinki guidelines. The Ethics Committee (IRB) granting this APPROVAL is in compliance with the Guidelines for Good Practice in the Conduct of Clinical Trials in Human Participants in South Africa (2006), ICH Harmonised Tripartite Guidelines E6: Note: for the Guidance in Good Clinical Practice (CPMP/ICH/135/95) and FDA Code of Federal Regulation Part 50, 56 and 312.” Informed consent was obtained from all the participants in this study by means of a voluntarily completed consent form, included in the SI.
All authors have given their approval of the version of the manuscript as submitted, their consent for publication and agreed to the accountability requirements.
- Brown, G. K., Cromby, C. H., Manning, N. J., & Pollitt, R. J. (1987). Urinary organic acids in succinic semialdehyde dehydrogenase deficiency: Evidence of α-oxidation of 4-hydroxybutyric acid, interaction of succinic semialdehyde with pyruvate dehydrogenase and possible secondary inhibition of mitochondrial β-oxidation. Journal of Inherited Metabolic Disease, 10(4), 367–375.CrossRefGoogle Scholar
- Henström, M., & D’Amato, M. (2016). Genetics of irritable bowel syndrome. Molecular and Cellular Neuroscience, 3(1), 7.Google Scholar
- Isono, M., Nakanishi, I., Sasajima, K. I., Motizuki, K., Kanzaki, T., Okazaki, H., et al. (1968). 2-Keto-l-gulonic acid fermentation: Part I. Paper chromatographic characterization of metabolic products from sorbitol and l-sorbose by various bacteria. Agricultural Biological Chemistry, 32(4), 424–431.Google Scholar
- Levine, J. S., & Burakoff, R. (2011). Extraintestinal manifestations of inflammatory bowel disease. Gastroenterology & Hepatology (NY), 7(4), 235–241.Google Scholar
- Mason, S., Moutloatse, G. P., van Furth, M. A., Solomons, R., van Reenen, M., Reinecke, C. J., et al. (2014). KEMREP: A new qualitative method for the assessment of an analyst’s ability to generate a metabolomics data matrix by gas chromatography–mass spectrometry. Current Metabolomics, 2(1), 15–26.CrossRefGoogle Scholar
- McFarland, L. V. (2014). Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: A systematic review. British Medical Journal Open, 4(8), e005047.Google Scholar
- van der Heiden, E., Delmarcelle, M., Lebrun, S., Freichels, R., Brans, A., Vastenavond, C. M., et al. (2013). A pathway closely related to the d-tagatose pathway of Gram-negative enterobacteria identified in the Gram-positive bacterium Bacillus licheniformis. Applied and Environmental Microbiology, 79(11), 3511–3515.CrossRefGoogle Scholar